سعر اتموسالازين 500 مجم 50 كبسولة ممتدة المفعول 2024

Mesalazine 500 mg extended-release capsules, an aminosalicylate intestinal anti-inflammatory, listed in Egypt under ATCO Pharma / ATM Pharmaceutical Industries; pack of 50 capsules (5 strips x 10).

• Induction of remission and treatment of mildly to moderately active ulcerative colitisPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (over 1%): diarrhoea (3%), headache (2%), nausea (2%), abdominal pain (1%), dyspepsia (1%), vomiting (2%) and rash (1%).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known or suspected hypersensitivity to salicylates, aminosalicylates or any component of the capsules.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Renal impairment (minimal change nephropathy, interstitial nephritis, renal failure): assess renal function before and during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Mesalamine-induced acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhoea, sometimes fever, headache, rash) may mimic a colitis flare: discontinue if suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity reactions including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis and blood abnormalities; hepatic failure in patients with liver disease; severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP): discontinue at first signs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Nephrotoxic agents including NSAIDsIncreased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions.DailyMed (U.S. National Library of Medicine)
• Azathioprine or 6-mercaptopurineIncreased risk of blood disorders, bone marrow failure and associated complications; monitor complete blood counts and platelet counts if used together.DailyMed (U.S. National Library of Medicine)

• Published data from meta-analyses, cohort studies and case series on mesalamine use in pregnancy have not reliably shown an association with major birth defects, miscarriage or adverse maternal or fetal outcomes; no adverse developmental effects in animal studies.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Mesalamine and its N-acetyl metabolite are present in human milk in small amounts (relative infant dose 0.1% or less); diarrhoea has been reported in breastfed infants: monitor the infant for diarrhoea.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Mesalazine: Mechanism not fully understood; appears to act locally on the colonic mucosa, possibly by reducing inflammatory mediator production (cyclooxygenase and lipoxygenase pathways) (US PENTASA label).